A5035798552- Bone health and treatments
- Cancer Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Radiopharmaceutical Chemistry and Applications
- HER2/EGFR in Cancer Research
- Bone and Joint Diseases
- Bone health and osteoporosis research
- Management of metastatic bone disease
- Brain Metastases and Treatment
- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Estrogen and related hormone effects
- Prostate Cancer Treatment and Research
- Oral health in cancer treatment
- Cancer Cells and Metastasis
- Monoclonal and Polyclonal Antibodies Research
- Lung Cancer Research Studies
- Bone Metabolism and Diseases
- Medical Imaging and Pathology Studies
- Cancer Risks and Factors
- BRCA gene mutations in cancer
- Head and Neck Cancer Studies
- Drug-Induced Ocular Toxicity
University of Michigan–Ann Arbor
2015-2024
Michigan Center for Translational Pathology
2011-2022
Michigan Medicine
2015-2020
U-M Rogel Cancer Center
2020
American Society for Bone and Mineral Research
2020
Dana-Farber Cancer Institute
2012-2018
The University of Texas MD Anderson Cancer Center
2011-2018
Brigham and Women's Hospital
2016-2018
Georgetown University
2016-2018
Mayo Clinic in Florida
2018
•The clinical course of advanced cancer for many patients with bone metastases can be transformed through optimum multidisciplinary management.•Bone-targeted agents significantly reduce skeletal morbidity in across tumour types and should part standard treatment.•Treatment-induced loss increases fracture risk may require use a bone-targeted agent addition to lifestyle modifications.•The bisphosphonate adjuvant therapies postmenopausal early breast reduces recurrence improves survival.
To provide recommendations on the appropriate use of breast tumor biomarker assay results to guide decisions systemic therapy for metastatic cancer.A literature search and prospectively defined study selection identified systematic reviews, meta-analyses, randomized controlled trials (RCTs), prospective-retrospective studies, prospective comparative observational studies published from 2006 through September 2014.The revealed 17 articles that met criteria further review: 11 reporting...
Purpose To update the recommendations on role of bone-modifying agents in prevention and treatment skeletal-related events (SREs) for patients with metastatic breast cancer bone metastases. Methods A literature search using MEDLINE Cochrane Collaboration Library identified relevant studies published between January 2003 November 2010. The primary outcomes interest were SREs time to SRE. Secondary included adverse pain. An Update Committee reviewed re-evaluated previous recommendations....
Evidence-based treatments for metastatic, human epidermal growth factor receptor 2 (HER2)-positive breast cancer to the CNS are limited. We previously reported modest activity of neratinib monotherapy HER2-positive brain metastases. Here we report results from additional study cohorts.Patients with measurable, progressive, metastases (92% after receiving surgery and/or radiotherapy) received 240 mg orally once per day plus capecitabine 750 mg/m2 twice 14 days, then 7 days off....
Bone metastasis is mediated by complex interactions between tumor cells and resident stromal in the bone microenvironment. The functions of metalloproteinases organ-specific remain poorly defined despite their well-appreciated role matrix degradation invasion. Here, we show a mechanism whereby two distinct metalloproteinases, disintegrin metalloproteinase with thrombospondin motifs (ADAMTS1) metalloproteinase-1 (MMP1), orchestrate paracrine signaling cascade to modulate microenvironment...
Purpose This focused update addresses the use of MammaPrint (Agendia, Irvine, CA) to guide decisions on adjuvant systemic therapy. Methods ASCO uses a signals approach facilitate guideline updates. For this update, publication phase III randomized MINDACT (Microarray in Node-Negative and 1 3 Positive Lymph Node Disease May Avoid Chemotherapy) study evaluate assay 6,693 women with early-stage breast cancer provided signal. An expert panel reviewed results along other published literature...
This focused update addresses the use of Oncotype DX in guiding decisions on adjuvant systemic therapy.ASCO uses a signals approach to facilitate guideline updating. For this update, publication Trial Assigning Individualized Options for Treatment (TAILORx) evaluating noninferiority endocrine therapy alone versus chemoendocrine invasive disease-free survival women with scores provided signal. An expert panel reviewed results TAILORx along other published literature assay assess evidence...
The ATEMPT trial was designed to determine if treatment with trastuzumab emtansine (T-DM1) caused less toxicity than paclitaxel plus (TH) and yielded clinically acceptable invasive disease-free survival (iDFS) among patients stage I human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC).Patients centrally confirmed HER2+ BC were randomly assigned 3:1 T-DM1 or TH received 3.6 mg/kg IV every 3 weeks for 17 cycles T 80 mg/m2 H once week × 12 (4 load →2 mg/kg), followed by...
To report on the longitudinal cognitive functioning of older women receiving adjuvant chemotherapy for breast cancer.Neuropsychological and functional status testing were performed before 6 months after chemotherapy.Cancer center.Thirty-one patients aged 65 with Stage I to III cancer. Of 31 enrolled, three refused post-testing, 28 evaluable.The following domains function examined: attention; verbal memory; visual verbal, spatial, psychomotor, executive functions.Participants had a mean age...
Purpose To investigate the management of bone health in women with early breast cancer (EBC) who were scheduled to receive anastrozole. Patients and Methods Postmenopausal hormone receptor–positive EBC assigned one three strata by risk fragility fracture. highest (H) received anastrozole 1 mg/d plus risedronate 35 mg/wk orally. moderate-risk (M) randomly a double-blind manner (A + R) or placebo P). lower-risk (L) (A) alone. Calcium vitamin D recommended for all patients. Lumbar spine total...
Bone health and maintenance of bone integrity are important components comprehensive cancer care in both early late stages disease. Risk factors for osteoporosis increased patients with cancer, including women chemotherapy-induced ovarian failure, those treated aromatase inhibitors breast men receiving androgen-deprivation therapy prostate undergoing glucocorticoid therapy. The skeleton is a common site metastatic recurrence, skeletal-related events the cause significant morbidity. National...
Evidence-based treatments for metastatic, human epidermal growth factor receptor 2 (HER2)-positive breast cancer in the CNS are limited. Neratinib is an irreversible inhibitor of erbB1, HER2, and erbB4, with promising activity HER2-positive cancer; however, its unknown. We evaluated efficacy treatment neratinib patients brain metastases a multicenter, phase II open-label trial.Eligible were those (≥ 1 cm longest dimension) who experienced progression after one or more line CNS-directed...
Cases of osteonecrosis the jaw (ONJ) have been reported with an increasing frequency over past 5 years. ONJ is most often identified in patients cancer who are receiving intravenous bisphosphonate (IVBP) therapy, but it has also diagnosed oral bisphosphonates for nonmalignant conditions. To further categorize risk factors associated and potential clinical outcomes this condition, we performed a retrospective study metastatic bone disease treated evaluated by Memorial Sloan-Kettering Cancer...